Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

Recombinant human erythropoietin (r-HuEpo) has been used for the treatment of renal anemia. With the loss of its patent protection, there has been an upsurge of more affordable biosimilar agents, increasing patient access to treatment for these conditions. The complexity of the manufacturing process...

Full description

Saved in:
Bibliographic Details
Main Authors: Kearkiat Praditpornsilpa, Khajohn Tiranathanagul, Pawinee Kupatawintu, Saengsuree Jootar, Tanin Intragumtornchai, Kriang Tungsanga, Tanyarat Teerapornlertratt, Dusit Lumlertkul, Natavudh Townamchai, Paweena Susantitaphong, Pisut Katavetin, Talerngsak Kanjanabuch, Yingyos Avihingsanon, Somchai Eiam-Ong
Format: Journal
Published: 2018
Subjects:
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79958824101&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50306
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79958824101&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50306

Similar Items